| Product dosage: 180mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.38 | $101.47 (0%) | 🛒 Add to cart |
| 60 | $2.71 | $202.94 $162.75 (20%) | 🛒 Add to cart |
| 90 | $2.50 | $304.41 $225.04 (26%) | 🛒 Add to cart |
| 120 | $2.38 | $405.87 $285.32 (30%) | 🛒 Add to cart |
| 180 | $2.27 | $608.81 $407.88 (33%) | 🛒 Add to cart |
| 270 | $2.20
Best per pill | $913.22 $592.74 (35%) | 🛒 Add to cart |
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.82 | $49.23 (0%) | 🛒 Add to cart |
| 90 | $0.78 | $73.84 $70.32 (5%) | 🛒 Add to cart |
| 120 | $0.76 | $98.45 $91.42 (7%) | 🛒 Add to cart |
| 180 | $0.74 | $147.68 $132.61 (10%) | 🛒 Add to cart |
| 270 | $0.73 | $221.52 $195.90 (12%) | 🛒 Add to cart |
| 360 | $0.72
Best per pill | $295.36 $258.19 (13%) | 🛒 Add to cart |
Similar products
More info:
diltiazem
Diltiazem hydrochloride represents one of the most versatile cardiovascular agents in our modern pharmacopeia, a calcium channel blocker with a fascinatingly specific mechanism that sets it apart from other drugs in its class. When I first encountered this medication during my cardiology fellowship back in the early 2000s, we were still unraveling its full potential beyond basic hypertension management. The drug’s unique ability to selectively target vascular smooth muscle and cardiac nodal tissue without significant negative inotropic effects made it particularly valuable for patients with multiple comorbidities.
adalat
Product Description: Adalat is a calcium channel blocker medication containing nifedipine as its active pharmaceutical ingredient. It’s primarily prescribed for managing hypertension and chronic stable angina, working by relaxing blood vessels to improve blood flow and reduce cardiac workload. Available in various formulations including immediate-release capsules and extended-release tablets, Adalat represents one of the first-generation dihydropyridine calcium antagonists that revolutionized cardiovascular treatment when introduced decades ago. I remember when we first started using Adalat in our cardiology department back in the late 80s - we were frankly skeptical about this new class of drugs.
atorlip 20
Atorlip 20 represents the latest evolution in targeted lipid management, combining 20mg of atorvastatin with a phospholipid delivery system that fundamentally changes how we approach statin therapy. What started as a research project back in 2018 has become what I now consider an essential tool for patients who either can’t tolerate standard statins or need that extra push to reach their LDL targets. I remember when we first started developing this formulation - there was significant pushback from our pharmaceutical partners who argued that the phospholipid technology would drive costs up without clear benefits.
buspar
Buspirone hydrochloride represents one of the more interesting anxiolytics in our armamentarium – it’s not a benzodiazepine, doesn’t cause significant sedation or dependence, yet many clinicians remain uncertain about its optimal use. The drug exists in this curious space between traditional anti-anxiety medications and newer antidepressants with anxiolytic properties. Buspar: Effective Anxiety Management Without Sedation or Dependence - Evidence-Based Review 1. Introduction: What is Buspar? Its Role in Modern Medicine Buspirone hydrochloride, marketed as Buspar, belongs to the azapirone class of medications and functions as a serotonin 5-HT1A receptor partial agonist.
Bystolic: Selective Beta-Blockade with Vasodilatory Benefits for Hypertension - Evidence-Based Review
Bystolic represents one of those interesting cases where the pharmacological profile promised something different from existing beta-blockers, and in my fifteen years managing hypertension clinic patients, I’ve found it largely delivers. The drug’s proper name is nebivolol, and it occupies this unique space as a third-generation beta-1 selective adrenergic receptor blocker with additional nitric oxide-mediated vasodilation. We initially started using it around 2008 when it gained FDA approval, mostly for patients who couldn’t tolerate the bronchoconstriction or metabolic side effects of older agents like propranolol or even metoprolol.
calan
Calan, known generically as verapamil, represents one of the foundational calcium channel blockers in cardiovascular therapeutics. Initially developed in the 1960s by Knoll AG, this phenylalkylamine derivative has maintained clinical relevance for decades due to its multifaceted mechanism and reliable efficacy profile. Unlike dihydropyridine calcium channel blockers that predominantly affect vascular smooth muscle, verapamil exhibits significant activity on both cardiac and vascular tissues, making it particularly valuable for managing supraventricular tachyarrhythmias and hypertension.
Cardizem: Effective Blood Pressure and Heart Rhythm Control - Evidence-Based Review
Cardizem, known generically as diltiazem, is a calcium channel blocker primarily used in the management of cardiovascular conditions such as hypertension, angina, and certain arrhythmias. It functions by inhibiting the influx of calcium ions into cardiac and vascular smooth muscle, leading to vasodilation and reduced myocardial oxygen demand. Available in various formulations including immediate-release tablets, extended-release capsules, and intravenous preparations, Cardizem is a cornerstone therapy in cardiology due to its efficacy and relatively favorable side effect profile.
colchicine
Colchicine is a naturally occurring alkaloid derived from the autumn crocus (Colchicum autumnale) and Gloriosa superba plants. This ancient remedy has been used since the first century AD for inflammatory conditions, but its modern pharmaceutical formulation represents one of the most specific anti-inflammatory agents in our therapeutic arsenal. Unlike broad-spectrum NSAIDs or corticosteroids, colchicine targets microtubule polymerization with remarkable precision, making it particularly valuable for crystal-induced arthropathies and, more recently, for cardiovascular inflammation.
coreg
Carvedilol, marketed under the brand name Coreg, represents a significant advancement in cardiovascular pharmacotherapy. As a non-selective beta-blocker with additional alpha-1 blocking properties, this medication occupies a unique position in managing various cardiac conditions. Unlike traditional beta-blockers, carvedilol’s dual mechanism provides comprehensive adrenergic blockade, making it particularly valuable in heart failure management where sympathetic nervous system activation contributes significantly to disease progression. The development journey wasn’t straightforward though - I remember when we first started using carvedilol in our cardiology practice back in the late 90s, there was considerable skepticism about whether this “fancy new beta-blocker” offered any real advantages over established agents like metoprolol.